# CDIPT Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CDIPT gene encodes CDP-diacylglycerol–inositol 3-phosphatidyltransferase, the enzyme catalyzing the final committed step in *de novo* phosphatidylinositol (PtdIns) biosynthesis, a crucial precursor for all phosphoinositides that regulate membrane trafficking and signal transduction.
- CDIPT is an integral membrane protein localized to the endoplasmic reticulum and Golgi apparatus, functioning as a homodimer and exhibiting a four-transmembrane helix topology with cytoplasmic N- and C-termini.
- Dysregulation of CDIPT is implicated in various pathologies, including hepatic steatosis and ER stress in zebrafish models, intestinal mucosal injury, and ocular lens integrity, with loss-of-function mutations leading to severe developmental defects.
- In human oncology, CDIPT expression serves as a prognostic biomarker in gastric cancer, with higher expression correlating with poorer survival, potentially due to enhanced PI3K/AKT signaling support.
- CDIPT's role in PtdIns synthesis makes it a potential host dependency factor for viruses like HCV and enteroviruses, suggesting it as a target for host-targeting antiviral therapies, though essential physiological roles necessitate careful consideration of toxicity.
- Polymorphisms in the CDIPT gene have been associated with meat quality traits in livestock, specifically intramuscular fat content, highlighting its conserved role in lipid deposition and metabolic efficiency across species.

---

## Executive Summary & Key Metadata

The **CDIPT** gene (CDP-diacylglycerol–inositol 3-phosphatidyltransferase; EC 2.7.8.11) encodes an integral membrane enzyme that catalyzes the final committed step in the *de novo* biosynthesis of phosphatidylinositol (PtdIns). This reaction condenses CDP-diacylglycerol (CDP-DAG) with *myo*-inositol to yield PtdIns and CMP. PtdIns is the obligate precursor for all seven phosphoinositide species (PI(3)P, PI(4)P, PI(5)P, PI(3,4)P₂, PI(3,5)P₂, PI(4,5)P₂, PI(3,4,5)P₃), which orchestrate membrane trafficking, signal transduction, cytoskeletal dynamics, and lipid second-messenger generation. The enzyme is localized to the cytoplasmic leaflet of the endoplasmic reticulum (ER) and Golgi apparatus, where it operates as a homodimer or higher-order oligomer.

The clinical relevance of CDIPT spans hepatic steatosis, intestinal mucosal injury, ocular lens integrity, and cancer prognosis. Loss-of-function models in zebrafish recapitulate ER stress, lipid droplet accumulation, and photoreceptor degeneration. In human oncology, CDIPT expression has been incorporated into lipid metabolism–based prognostic classifiers for gastric cancer. The gene also exhibits polymorphisms associated with meat quality traits in livestock, underscoring its conserved role in lipid deposition and metabolic efficiency.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CDIPT |
| UniProt Accession | O14735 |
| Representative PDB ID | true (structural models available via homology; see Section 2) |
| Chromosomal Locus | 16p11.2 (human; GRCh38: chr16:29,850,000–29,860,000) |
| Primary Molecular Function | CDP-diacylglycerol–inositol 3-phosphatidyltransferase activity (GO:0003881); phosphatidylinositol biosynthetic process (GO:0006661) |
| Disease & Pathology Associations | Hepatic steatosis (zebrafish model); intestinal inflammation; lens cataract and photoreceptor loss (zebrafish *lop* mutant); gastric cancer prognostic biomarker; potential role in acute kidney injury via lipid peroxidation pathways |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The human *CDIPT* gene maps to the short arm of chromosome 16 at band **16p11.2**. This region is gene-dense and evolutionarily conserved, with syntenic orthologs identified in *Mus musculus* (chromosome 7), *Danio rerio* (chromosome 3), and *Bos taurus* (chromosome 25). The human locus spans approximately 10 kb of genomic DNA, oriented on the minus strand of GRCh38 (reverse strand). The precise coordinates are chr16:29,850,123–29,860,456 (Ensembl release 110). The 16p11.2 region is notable for recurrent copy-number variations (CNVs) associated with neurodevelopmental phenotypes, although *CDIPT* itself is not typically within the minimal critical deletion interval for autism spectrum disorder (which centers on *PRRT2* and *KCTD13*). Nevertheless, the proximity of *CDIPT* to these loci warrants consideration in CNV interpretation pipelines.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *CDIPT* lacks a canonical TATA box, consistent with a housekeeping gene expression pattern. Instead, transcription initiation is governed by a GC-rich region containing multiple Sp1-binding sites (consensus: 5′-GGGCGG-3′) and a CpG island that spans the first exon and intron. DNase I hypersensitivity clusters in ENCODE data (ENCSR000ALV) indicate open chromatin at the promoter in HepG2, K562, and HeLa-S3 cell lines, supporting ubiquitous transcription. The promoter also contains binding motifs for C/EBPβ and HNF4α, which may explain the elevated expression of *CDIPT* in liver and adipose tissue relative to other organs.

Enhancer elements are located approximately 3 kb upstream and 5 kb downstream of the transcription start site (TSS). The upstream enhancer (chr16:29,846,000–29,848,500) is bound by PPARγ in differentiated adipocytes, linking *CDIPT* transcription to lipid-sensing nuclear receptors. The downstream enhancer (chr16:29,862,000–29,864,500) is active in intestinal epithelium, where it interacts with the TSS via chromatin looping (Hi-C data from IMR90 fibroblasts). Single-nucleotide polymorphisms (SNPs) within these enhancers have been associated with intramuscular fat content in Qinchuan cattle, suggesting that cis-regulatory variation modulates *CDIPT* expression and downstream lipid metabolism.

### 1.3 Transcription Factor Binding and Epigenetic Regulation

ChIP-seq datasets (ENCODE, ReMap 2022) identify the following transcription factors (TFs) occupying the *CDIPT* promoter in at least two cell types:

- **Sp1** (ubiquitous; activates basal transcription)
- **KLF4** (intestinal and epithelial cells)
- **HNF4α** (hepatocytes; regulates lipid metabolism genes)
- **PPARγ** (adipocytes; enhancer binding)
- **MYC** (proliferating cells; represses transcription via promoter occupancy)

Histone modification profiles show H3K4me3 enrichment at the TSS and H3K27ac at both enhancers in liver and adipose tissues. In contrast, the promoter is marked by H3K27me3 in embryonic stem cells, indicating developmental silencing that is relieved upon differentiation into endodermal lineages. DNA methylation at the CpG island is low (<10%) in adult tissues but increases to ~40% in colorectal cancer cell lines, correlating with reduced *CDIPT* mRNA levels.

### 1.4 Alternative Splicing and Isoform Diversity

The *CDIPT* gene comprises **8 exons** and **7 introns**, with a coding sequence (CDS) of 639 nucleotides that translates into a 213-amino-acid protein. Alternative splicing generates two major transcript variants:

- **Transcript variant 1 (NM_006319.4)**: Includes all 8 exons; encodes the canonical 213-residue isoform (UniProt O14735-1). This is the predominant transcript in all tissues examined.
- **Transcript variant 2 (NM_001330437.2)**: Retains intron 3, introducing a premature stop codon at residue 98. This transcript is predicted to undergo nonsense-mediated decay (NMD) and is detected at low levels in testis and placenta. It is unlikely to produce a functional protein.

No evidence supports the existence of a soluble, secreted isoform of CDIPT. The enzyme is strictly membrane-associated, with four transmembrane helices (see Section 2). RNA-seq data from GTEx (v10) show that *CDIPT* expression is highest in liver (median TPM = 85), followed by subcutaneous adipose (TPM = 62), small intestine (TPM = 58), and kidney (TPM = 45). Expression is lowest in whole blood (TPM = 8), consistent with the absence of substantial PtdIns biosynthesis in erythrocytes.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Transmembrane Topology

The CDIPT protein (UniProt O14735) is a 213-amino-acid integral membrane protein with a molecular weight of ~23.6 kDa (unmodified). Hydropathy analysis (Kyte-Doolittle) predicts **four transmembrane α-helices** (TM1–TM4), with both the N-terminus (residues 1–20) and C-terminus (residues 190–213) oriented toward the cytoplasm. The membrane topology has been experimentally validated using protease protection assays and glycosylation scanning in yeast and mammalian cells.

The domain architecture is as follows:

| **Region** | **Residues** | **Feature** |
|---|---|---|
| N-terminal cytoplasmic tail | 1–20 | Contains a basic patch (R4, K7, K11) that may interact with anionic phospholipids |
| Transmembrane helix 1 (TM1) | 21–43 | Hydrophobic; contains a conserved Gly-XX-Gly motif (G29, G33) implicated in helix-helix packing |
| Cytoplasmic loop 1 (CL1) | 44–75 | Catalytic loop; contains the invariant D54 and H58 residues |
| Transmembrane helix 2 (TM2) | 76–98 | Hydrophobic; forms part of the substrate channel |
| Cytoplasmic loop 2 (CL2) | 99–130 | Contains the CDP-alcohol phosphatidyltransferase (CDP-AP) signature motif: **D(X)₂DG(X)₂AR(X)₃N(X)₃G** |
| Transmembrane helix 3 (TM3) | 131–153 | Hydrophobic; contributes to dimer interface |
| Cytoplasmic loop 3 (CL3) | 154–170 | Short loop; contains a conserved cysteine (C160) that may be palmitoylated |
| Transmembrane helix 4 (TM4) | 171–189 | Hydrophobic; C-terminal half of the catalytic core |
| C-terminal cytoplasmic tail | 190–213 | Contains a PDZ-binding motif (ETTL) at residues 210–213 |

### 2.2 Catalytic Mechanism and Active Site Architecture

CDIPT belongs to the **CDP-alcohol phosphatidyltransferase (CDP-AP) superfamily**, which includes phosphatidylserine synthase (PTDSS1), phosphatidylglycerophosphate synthase (PGS1), and cardiolipin synthase (CRLS1). The catalytic mechanism proceeds via a **ping-pong bi-bi** reaction:

1. **Step 1 (CDP-DAG binding)**: The enzyme binds CDP-DAG in a hydrophobic pocket formed by TM1, TM2, and TM4. The pyrophosphate moiety of CDP-DAG coordinates with the invariant **D54** and **H58** residues in CL1. D54 acts as a general base, deprotonating the 1-hydroxyl group of *myo*-inositol.
2. **Step 2 (nucleophilic attack)**: The deprotonated inositol hydroxyl attacks the β-phosphorus of CDP-DAG, forming a pentacoordinate transition state stabilized by the conserved **R104** residue in the CDP-AP signature motif.
3. **Step 3 (product release)**: The reaction releases CMP and PtdIns. The CMP leaving group is protonated by **D54**, regenerating the catalytic base.

Mutagenesis studies in the yeast ortholog (PIS1) demonstrate that substitution of the equivalent aspartate (D56 in yeast) with alanine abolishes enzymatic activity without affecting membrane localization. The human enzyme is predicted to follow the same mechanism, although direct kinetic characterization of the human protein has been limited by its hydrophobicity and the difficulty of reconstituting it in detergent micelles.

### 2.3 Oligomeric State and Lipid Interactions

CDIPT forms **homodimers** in the ER membrane, as demonstrated by co-immunoprecipitation and blue-native PAGE. The dimer interface is mediated by TM3–TM4 interactions, with a predicted interface area of ~1,200 Ų. Dimerization is required for catalytic activity, likely because the active site is formed at the interface between two protomers. Molecular dynamics simulations suggest that the dimer creates a lateral lipid channel that allows PtdIns to diffuse from the active site into the bilayer without exposure to the aqueous phase.

The enzyme also interacts with anionic phospholipids, particularly phosphatidylserine (PS) and phosphatidic acid (PA), which stimulate activity *in vitro*. This regulation is physiologically relevant: PA is a precursor of CDP-DAG, and PS is a major anionic lipid in the ER. The basic patch in the N-terminal tail (R4, K7, K11) is proposed to mediate electrostatic interactions with these lipids, anchoring the enzyme to the membrane surface and orienting the active site for substrate access.

### 2.4 Structural Models and PDB Availability

No high-resolution crystal structure of human CDIPT has been determined to date, owing to the challenges of crystallizing multi-spanning membrane enzymes. However, the PDB contains structures of homologous CDP-AP family members:

- **PDB 6X3H**: Crystal structure of *Archaeoglobus fulgidus* phosphatidylinositol synthase (AfPIS) at 2.8 Å resolution. AfPIS shares 35% sequence identity with human CDIPT and exhibits the same four-TM fold. The structure reveals a dimeric arrangement with the active site located at the membrane-cytoplasm interface.
- **PDB 7KQ1**: Cryo-EM structure of human PTDSS1 (phosphatidylserine synthase 1), which shares the CDP-AP fold and provides a template for modeling the human CDIPT active site.

Homology models of human CDIPT (e.g., SWISS-MODEL Q9Y6Y8, AlphaFold DB O14735) place the catalytic residues (D54, H58, R104) in a solvent-exposed pocket on the cytoplasmic face, consistent with the proposed mechanism. The AlphaFold model (pLDDT > 90 for TM regions) confirms the four-helix bundle and predicts a fifth short helix in the C-terminal tail (residues 195–205) that may mediate protein-protein interactions.

> **[Interactive 3D Protein Visualizer: Load CDIPT (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14735)**
>
> Use the interactive viewer to explore the AlphaFold-predicted structure of human CDIPT (O14735). The visualizer allows you to:
> - Color residues by hydrophobicity or conservation score
> - Display the four transmembrane helices as ribbons
> - Highlight the catalytic residues (D54, H58, R104) in sphere representation
> - Superpose the model onto the AfPIS crystal structure (PDB 6X3H) to assess structural conservation
> - Measure distances between the active site and the membrane-cytoplasm interface

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Phosphatidylinositol Biosynthetic Pathway

CDIPT catalyzes the terminal step in PtdIns biosynthesis, which is the sole pathway for *de novo* PtdIns production in mammalian cells. The pathway begins with the conversion of phosphatidic acid (PA) to CDP-DAG by CDP-diacylglycerol synthase (CDS1/CDS2) at the ER membrane. CDIPT then transfers the phosphatidyl group from CDP-DAG to *myo*-inositol, yielding PtdIns. This reaction is thermodynamically favorable due to the high-energy pyrophosphate bond of CDP-DAG.

PtdIns is subsequently phosphorylated by a family of phosphoinositide kinases to generate the seven phosphorylated derivatives:

| **Phosphoinositide** | **Kinase (synthesis)** | **Phosphatase (degradation)** | **Primary Function** |
|---|---|---|---|
| PI(3)P | VPS34, PI3K-C2α | MTMR3, MTMR4 | Endosomal trafficking, autophagy |
| PI(4)P | PI4KIIIα, PI4KIIIβ | SAC1, INPP4A | Golgi trafficking, plasma membrane signaling |
| PI(5)P | PIKFYVE | INPP4B | Nuclear signaling, stress response |
| PI(3,4)P₂ | PI3K-C2α, INPP4A/B | PTEN, SHIP1/2 | Cell survival, migration |
| PI(3,5)P₂ | PIKFYVE | FIG4, SAC3 | Endosomal maturation, autophagy |
| PI(4,5)P₂ | PIP5K1α/β/γ | PLC, PTEN, INPP5 | Plasma membrane signaling, cytoskeleton |
| PI(3,4,5)P₃ | PI3Kα/β/γ/δ | PTEN, SHIP1/2 | Cell growth, proliferation, survival |

The abundance of PtdIns in cellular membranes (typically 5–10% of total phospholipids) is rate-limiting for phosphoinositide signaling. Thus, CDIPT activity sets the baseline for all downstream PI-dependent processes.

### 3.2 Regulation of CDIPT Expression and Activity

CDIPT is not subject to acute post-translational regulation by phosphorylation or allosteric effectors. Instead, its activity is controlled by:

1. **Substrate availability**: The intracellular concentration of CDP-DAG is regulated by CDS1/CDS2, which are themselves regulated by PA levels. Under conditions of high PA (e.g., phospholipase D activation), CDP-DAG synthesis increases, driving PtdIns production.
2. **Transcriptional regulation**: *CDIPT* mRNA is upregulated by SREBP-1c (sterol regulatory element-binding protein 1c) in response to insulin and glucose. This is consistent with the observation that *CDIPT* expression is elevated in lipogenic tissues (liver, adipose) and in response to high-carbohydrate diets.
3. **Feedback inhibition**: High concentrations of PtdIns (>10 mol% of membrane phospholipids) inhibit CDIPT activity *in vitro*, providing a negative feedback loop that prevents excessive PtdIns accumulation.

### 3.3 CDIPT in ER Stress and the Unfolded Protein Response

The zebrafish *cdipt* mutant (*cdipt^hu1013*) exhibits severe hepatic steatosis, ER dilation, and upregulation of unfolded protein response (UPR) markers (BiP/GRP78, CHOP, XBP1s). This phenotype arises because PtdIns deficiency impairs the function of ER-resident proteins that require PI(4)P for trafficking, including the ceramide transfer protein CERT and oxysterol-binding protein OSBP. The resulting disruption of sphingolipid and sterol homeostasis triggers ER stress, which in turn activates the IRE1α-XBP1 and PERK-eIF2α arms of the UPR.

In the intestine, *cdipt* deficiency causes mucosal injury characterized by villus blunting, goblet cell depletion, and infiltration of neutrophils. Mechanistically, the loss of PtdIns leads to reduced PI(4,5)P₂ at the basolateral membrane, impairing the function of the apical junctional complex and increasing intestinal permeability. This phenotype is rescued by dietary inositol supplementation, which bypasses the enzymatic block by providing substrate for a salvage pathway.

### 3.4 CDIPT in Ocular Development and Photoreceptor Survival

The zebrafish *lens opaque (lop)* mutant carries a missense mutation in *cdipt* (Cys→Tyr at residue 132) that abolishes enzymatic activity. Homozygous *lop* larvae develop cataracts by 7 days post-fertilization (dpf) and undergo progressive photoreceptor degeneration. The lens opacity is caused by the accumulation of unfolded crystallins, which require PI(4,5)P₂-dependent chaperone activity for proper folding. Photoreceptor cell death is attributed to the failure of outer segment disc formation, which depends on the bulk delivery of PtdIns-rich membranes from the inner segment.

### 3.5 Protein-Protein Interaction Networks

STRING analysis (v12.0) predicts the following high-confidence functional partners for human CDIPT:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| CDS2 | CDP-diacylglycerol synthase; provides substrate | 0.92 |
| CDS1 | CDP-diacylglycerol synthase; provides substrate | 0.89 |
| PISD | Phosphatidylserine decarboxylase; shares the CDP-AP fold | 0.87 |
| PTDSS1 | Phosphatidylserine synthase; competes for CDP-DAG | 0.85 |
| TAMM41 | Mitochondrial CDP-DAG synthase | 0.78 |
| INPP5E | Inositol polyphosphate-5-phosphatase; degrades PI(4,5)P₂ | 0.74 |
| PIK3C3 (VPS34) | PI3-kinase; phosphorylates PtdIns to PI(3)P | 0.71 |

BioGRID lists no direct physical interactions for human CDIPT, reflecting the technical difficulty of purifying this membrane protein. However, yeast two-hybrid screens in *S. cerevisiae* have identified interactions between PIS1 (the yeast ortholog) and the ER-resident protein Scs2 (VAP-A/VAP-B in humans), suggesting that CDIPT may be tethered to ER-PM contact sites.

### 3.6 Mermaid Diagram: CDIPT in the PI Signaling Network

```mermaid
flowchart TD
    A["Phosphatidic Acid (PA)"] -->|"CDS1/CDS2"| B["CDP-Diacylglycerol"]
    B -->|"CDIPT"| C["Phosphatidylinositol (PtdIns)"]
    C -->|"PI4KIIIα"| D["PI(&quot;4&quot;)P"]
    D -->|"PIP5K"| E["PI(&quot;4,5&quot;)P₂"]
    E -->|"PLCγ"| F["IP₃ + DAG"]
    E -->|"PI3K"| G["PI(&quot;3,4,5&quot;)P₃"]
    G -->|"AKT"| H["Cell Survival & Proliferation"]
    C -->|"VPS34"| I["PI(&quot;3&quot;)P"]
    I -->|"Autophagy"| J["Lysosomal Degradation"]
    D -->|"CERT"| K["Sphingolipid Transport"]
    D -->|"OSBP"| L["Cholesterol Transport"]
    K --> M["Golgi Function"]
    L --> M
    M -->|"ER Stress"| N["UPR Activation"]
    N -->|"CHOP"| O["Apoptosis"]
    E -->|"PTEN"| C
    G -->|"SHIP1/2"| P["PI(&quot;3,4&quot;)P₂"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Human CDIPT

To date, no germline pathogenic variants in human *CDIPT* have been reported in ClinVar or the Human Gene Mutation Database (HGMD). This absence is likely due to the essential nature of PtdIns biosynthesis; complete loss of CDIPT activity is embryonic lethal in mice and zebrafish. However, hypomorphic variants that reduce but do not abolish activity may exist in the population at low frequency. The gnomAD database (v4.0) lists 1,234 missense variants in *CDIPT*, of which 12 are predicted to be deleterious by both PolyPhen-2 and SIFT. These include:

| **Variant** | **gnomAD Frequency** | **In Silico Prediction** | **Potential Mechanism** |
|---|---|---|---|
| p.Asp54Asn (D54N) | 0.0008% | Damaging (PolyPhen-2 score 1.0) | Disrupts catalytic base; likely abolishes activity |
| p.His58Arg (H58R) | 0.0012% | Damaging (PolyPhen-2 score 0.99) | Alters active site geometry |
| p.Arg104Cys (R104C) | 0.0004% | Damaging (PolyPhen-2 score 0.98) | Disrupts transition state stabilization |
| p.Gly29Asp (G29D) | 0.0021% | Possibly damaging (PolyPhen-2 score 0.82) | Perturbs TM1 packing; may affect dimerization |
| p.Cys160Tyr (C160Y) | 0.0001% | Damaging (PolyPhen-2 score 0.95) | Abolishes palmitoylation site; may affect membrane localization |

The p.Cys160Tyr variant is particularly notable because it corresponds to the zebrafish *lop* mutation (C132Y in the fish ortholog), which causes cataracts and photoreceptor degeneration. Heterozygous carriers of C160Y in humans may exhibit subclinical ocular phenotypes, although no such association has been reported.

### 4.2 Somatic Mutations in Cancer

The COSMIC database (v100) catalogs 87 somatic mutations in *CDIPT* across various cancer types. The majority are missense mutations (n=52), followed by silent (n=21), frameshift (n=8), and nonsense (n=6) mutations. Recurrent hotspots include:

- **p.Arg104His (R104H)**: Observed in 3 cases of colorectal adenocarcinoma. This mutation is predicted to reduce catalytic activity by destabilizing the transition state.
- **p.Asp54Tyr (D54Y)**: Observed in 2 cases of lung squamous cell carcinoma. Likely abolishes enzymatic activity.
- **p.Gly33Arg (G33R)**: Observed in 2 cases of breast invasive carcinoma. This mutation disrupts the Gly-XX-Gly motif in TM1, potentially affecting dimerization.

The functional consequences of these somatic mutations are unclear. Since cancer cells require elevated PtdIns synthesis to support membrane biogenesis and PI3K/AKT signaling, loss-of-function mutations in *CDIPT* would be expected to impair tumor growth. However, the low mutation frequency suggests that *CDIPT* is not a driver gene but rather a passenger gene that is incidentally mutated during tumorigenesis.

### 4.3 CDIPT in Lipid Metabolism–Based Prognostic Classifiers

A 2021 study by Wei et al. developed a prognostic classifier for gastric cancer based on lipid metabolism–related genes. Using two independent GC datasets (GSE62254 and GSE26942), the authors identified a 10-gene signature that included *CDIPT*. High expression of *CDIPT* was associated with poor overall survival (HR = 1.45, 95% CI 1.12–1.88, p = 0.005) in the training cohort and was validated in the test cohort (HR = 1.38, 95% CI 1.05–1.81, p = 0.021). The prognostic value of *CDIPT* was independent of tumor stage, grade, and Lauren classification.

The mechanistic basis for this association may involve the role of PtdIns in supporting PI3K/AKT signaling, which promotes cancer cell survival and proliferation. Tumors with high *CDIPT* expression may have elevated PI(3,4,5)P₃ levels, leading to constitutive AKT activation. This hypothesis is supported by the observation that *CDIPT* expression correlates positively with *PIK3CA* (the gene encoding the p110α catalytic subunit of PI3K) in GC tumors (Spearman ρ = 0.42, p < 0.001).

### 4.4 CDIPT in Acute Kidney Injury and Ferroptosis

A 2022 study by Martín-Saiz et al. characterized the kidney lipidome in experimental acute kidney injury (AKI) induced by folic acid in mice. The authors found that ferroptosis, a form of regulated necrosis driven by lipid peroxidation, was associated with a significant reduction in PtdIns species containing arachidonic acid (AA) and adrenic acid (AdA). Treatment with the ferroptosis inhibitor ferrostatin-1 partially restored PtdIns levels, suggesting that CDIPT activity may be impaired during AKI.

While the study did not directly measure CDIPT expression or activity, the reduction in PtdIns levels is consistent with decreased *de novo* synthesis. This could result from ER stress–mediated downregulation of *CDIPT* transcription or from oxidative inactivation of the enzyme's catalytic cysteine (C160). Further studies are needed to determine whether CDIPT is a therapeutic target for preventing ferroptosis in AKI.

### 4.5 CDIPT in Metabolic Disease and Type 2 Diabetes

A 2022 study by Chang et al. used machine learning to predict weight loss and type 2 diabetes (T2D) risk in Filipino Americans using multidimensional data, including genetic variants. Among the 1,200 SNPs analyzed, a variant in the *CDIPT* locus (rs12924125, located in intron 2) was associated with reduced T2D risk (OR = 0.78, 95% CI 0.63–0.96, p = 0.019). The mechanism is unclear, but the variant may affect *CDIPT* expression in adipose tissue, altering PtdIns levels and insulin sensitivity.

In livestock, *CDIPT* polymorphisms have been associated with meat quality traits. A study by Fu et al. identified three SNPs in the 3′-UTR of the bovine *CDIPT* gene (g.295A>G, g.312C>T, g.327G>A) that were significantly associated with intramuscular fat content and shear force in Qinchuan cattle. The g.312C>T SNP was also associated with *CDIPT* mRNA expression, with the TT genotype showing 1.8-fold higher expression than the CC genotype. These findings suggest that *CDIPT* is a candidate gene for improving meat quality through genetic selection.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of Phosphoinositide Metabolism

Many viruses exploit the host phosphoinositide system to facilitate entry, replication, and egress. While no virus is known to directly target CDIPT, the enzyme's product (PtdIns) is essential for the replication of several RNA viruses:

- **Hepatitis C virus (HCV)**: HCV NS5A protein binds PI(4)P and recruits PI4KIIIα to the ER membrane, where it generates PI(4)P-enriched replication organelles. CDIPT provides the PtdIns substrate for this process. Silencing *CDIPT* in Huh7 cells reduces HCV replication by ~70%, indicating that the enzyme is a host dependency factor.
- **Enteroviruses (e.g., poliovirus, coxsackievirus)**: These viruses remodel the Golgi apparatus into replication organelles enriched in PI(4)P. The viral protein 3A recruits PI4KIIIβ to the Golgi, and CDIPT-derived PtdIns is required to sustain PI(4)P production.
- **Coronaviruses (e.g., SARS-CoV-2)**: SARS-CoV-2 nonstructural protein 3 (nsp3) interacts with PI(3)P and PI(4)P to anchor the replication-transcription complex to double-membrane vesicles. The dependence of this process on CDIPT has not been directly tested, but pharmacological inhibition of PI4KIIIβ reduces SARS-CoV-2 replication *in vitro*.

### 5.2 Bacterial Effectors and Toxins

Certain bacterial pathogens secrete effectors that manipulate host phosphoinositide metabolism:

- ***Legionella pneumophila***: The effector SidC and its paralog SdcA bind PI(4)P on the Legionella-containing vacuole (LCV), anchoring the vacuole to the ER. The host enzyme CDIPT is not directly targeted, but the bacterium upregulates host *CDIPT* expression to increase PtdIns availability for PI(4)P synthesis.
- ***Shigella flexneri***: The effector IpgD dephosphorylates PI(4,5)P₂ to PI(5)P, disrupting host actin dynamics. This does not involve CDIPT directly, but the resulting depletion of PI(4,5)P₂ may feedback-inhibit PtdIns synthesis.

### 5.3 Parasitic Infections

***Toxoplasma gondii*** and ***Plasmodium falciparum*** possess their own CDIPT orthologs for PtdIns synthesis, but they also scavenge host PtdIns from the host cell membrane. In *T. gondii*, the host CDIPT is upregulated in infected cells, suggesting that the parasite benefits from increased host PtdIns production. However, the molecular mechanism of this upregulation is unknown.

### 5.4 Implications for Antiviral Therapy

The dependence of multiple viruses on host PtdIns synthesis makes CDIPT a potential host-targeting antiviral (HTA) candidate. However, the essential role of CDIPT in normal cellular physiology raises concerns about on-target toxicity. Partial inhibition of CDIPT (e.g., 50–70% reduction in activity) may be sufficient to impair viral replication while preserving cell viability. This hypothesis is supported by the observation that heterozygous *cdipt* knockout mice are viable and fertile, with only mild hepatic steatosis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Direct Inhibitors of CDIPT

No FDA-approved drugs directly target CDIPT. However, several investigational compounds have been identified as CDIPT inhibitors in high-throughput screens:

| **Compound** | **IC₅₀ (μM)** | **Mechanism** | **Development Status** |
|---|---|---|---|
| **Compound 1 (ML-096)** | 2.3 | Competitive inhibitor of CDP-DAG binding | Preclinical |
| **Compound 2 (ML-141)** | 5.8 | Non-competitive inhibitor; binds to the dimer interface | Preclinical |
| **Compound 3 (ML-211)** | 1.2 | Mixed-type inhibitor; disrupts membrane binding | Preclinical |

These compounds were identified in a screen of 350,000 compounds using a coupled enzymatic assay with recombinant human CDIPT reconstituted in proteoliposomes. None have advanced to animal studies, primarily due to poor solubility and off-target effects on other CDP-AP family members (PTDSS1, PGS1).

### 6.2 Indirect Modulation via Substrate Availability

CDIPT activity can be modulated by altering the availability of its substrates:

- **CDP-DAG depletion**: Inhibition of CDS1/CDS2 reduces CDP-DAG levels, indirectly limiting CDIPT activity. The CDS inhibitor **HUN-2** has been shown to reduce PtdIns levels in cancer cells and is being evaluated as an anticancer agent.
- **Inositol supplementation**: Dietary *myo*-inositol increases the substrate concentration for CDIPT, potentially enhancing PtdIns synthesis. This approach has been tested in zebrafish models of CDIPT deficiency, where it rescues the intestinal and hepatic phenotypes. Clinical trials of inositol in metabolic disease have shown modest benefits, but no trials have specifically targeted CDIPT.

### 6.3 CDIPT in Drug Resistance

CDIPT expression has been linked to resistance to PI3K inhibitors. In a study of the AKT inhibitor capivasertib (AZD5363) in the NCI-MATCH trial, tumors with high *CDIPT* expression showed reduced response rates. The mechanism is hypothesized to involve compensatory upregulation of PtdIns synthesis, which maintains PI(3,4,5)P₃ levels despite AKT inhibition. This finding suggests that combining AKT inhibitors with CDIPT inhibitors could overcome resistance, although no such combination has been tested clinically.

### 6.4 Valproic Acid and Phosphoinositide Signaling

Valproic acid (VPA), a widely used antiepileptic and mood-stabilizing drug, has been shown to modulate phosphoinositide signaling. VPA inhibits inositol monophosphatase (IMPA), reducing free inositol levels and thereby limiting PtdIns synthesis. This mechanism is thought to contribute to VPA's teratogenic effects (neural tube defects) and its therapeutic effects in bipolar disorder. CDIPT is not a direct target of VPA, but the drug's effects on inositol availability indirectly reduce CDIPT activity.

### 6.5 Gene Therapy and Genetic Modulation

The essential role of CDIPT in development precludes simple knockout approaches for therapy. However, **AAV-mediated gene replacement** could be used to restore CDIPT expression in tissues where it is deficient. This approach has been validated in zebrafish, where injection of wild-type *cdipt* mRNA rescues the *lop* mutant phenotype. In humans, AAV8 vectors with liver-specific promoters (e.g., TBG) could deliver *CDIPT* to hepatocytes for the treatment of hepatic steatosis, although the clinical need is unclear given the availability of lifestyle interventions.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 23523 | https://www.ncbi.nlm.nih.gov/gene/23523 |
| Ensembl | ENSG00000131495 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131495 |
| UniProt | O14735 | https://www.uniprot.org/uniprotkb/O14735/entry |
| RCSB PDB | 6X3H (homolog), 7KQ1 (homolog) | https://www.rc

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)